Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NovoCure Limited filings document the oncology device company's operating results, product and regulatory updates, and governance for its Tumor Treating Fields business. Recent Form 8-K reports include quarterly and annual financial results, FDA approval disclosure for Optune Pax, clinical-trial updates for pancreatic cancer, Medicare billing-status disclosure and executive compensatory arrangements.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. The filing record also identifies NovoCure as a Jersey-incorporated registrant under the Nasdaq ticker NVCR and records formal disclosures tied to its commercial products, clinical programs and reimbursement matters.
NovoCure Ltd reported that its Chief Human Resources Officer, Michal Nath Puri, acquired additional equity through an employee share plan. On June 30, 2026, Puri received 1,905 ordinary shares under the 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at $11.15 per share, a price determined as 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, as provided by the plan. Following this transaction, Puri directly holds 203,227 ordinary shares of NovoCure. The filing notes that this ESPP transaction is exempt under Rule 16b-3(c), reflecting a routine, compensation-related share acquisition rather than an open-market trade.
NovoCure Ltd’s Chief Executive Officer Leonard Frank X acquired 1,905 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at $11.15 per share, based on 85% of the closing price on January 1, 2026. Following this ESPP acquisition, he directly holds 461,425 ordinary shares. The transaction is described as exempt under Rule 16b-3(c).
NovoCure Ltd General Counsel Ben Arye Barak acquired 1,299 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at 85% of the January 1, 2026 closing price, at a reported price of $11.15 per share, bringing his direct holdings to 243,752 shares.
NovoCure Ltd director Asaf Danziger acquired 268 ordinary shares through the company’s 2025 Employee Share Purchase Plan (ESPP). The shares were purchased for $11.15 per share for the ESPP purchase period from January 1, 2026 through June 30, 2026.
Under the ESPP, the purchase price was set at 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, making this a routine compensation-related acquisition rather than an open-market trade. Following this transaction, Danziger directly owns 416,742 ordinary shares.
Novocure reported that its wearable device Optune Pax, which delivers Tumor Treating Fields, has received a CE Mark to treat adult patients with locally advanced pancreatic cancer of exocrine origin when used with gemcitabine and nab-paclitaxel in line with guideline recommendations. The approval is backed by the Phase 3 PANOVA-3 trial, where patients in the intent-to-treat group receiving Optune Pax plus chemotherapy achieved a median overall survival of 16.2 months versus 14.2 months on chemotherapy alone, and a significant 6.1‑month extension in median time to pain progression. In the modified intent-to-treat group, median overall survival reached 18.3 months with Optune Pax versus 15.1 months on chemotherapy alone. Optune Pax was generally well-tolerated, with mainly mild to moderate skin events and no device-related deaths reported.
Novocure reported topline data from its Phase 3 TRIDENT trial in newly diagnosed glioblastoma. The study tested starting Tumor Treating Fields (TTFields) at the beginning of chemoradiation versus starting during the maintenance phase.
The trial did not show a statistically significant improvement in the primary endpoint of overall survival for early initiation. Median overall survival in the intent-to-treat group was 17.7 months in the Early Start Arm versus 17.5 months in the Maintenance Start Arm (HR 0.953; p=0.519). One-, two- and three-year survival rates were similar between arms.
TTFields therapy, including initiation with chemoradiation, was well-tolerated with no new safety signals, and device-related safety remained consistent with prior TTFields studies in glioblastoma. Results have been accepted for presentation at the ASTRO 2026 Annual Meeting.
NovoCure Limited held its annual general meeting of shareholders, where investors re-elected eleven directors to serve until the 2027 meeting. Shareholders representing 93,826,730 ordinary shares, or approximately 81.01% of shares entitled to vote, were present in person or by proxy.
They approved the ratification of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as auditor for the fiscal year ending December 31, 2026, and supported executive compensation in a non-binding advisory vote. Shareholders also approved the Company’s Amended and Restated 2024 Omnibus Incentive Plan following a closely split vote between shares cast for and against.
NovoCure Ltd Chief Executive Officer Leonard Frank X reported a tax-related sale of 34,273 Ordinary Shares. The shares were sold in open-market transactions at a weighted average price of $17.9335 per share to cover tax withholding obligations arising from the vesting of Restricted Stock Units. According to the company’s equity incentive plan, this “sell to cover” transaction was mandated by the award agreement and is described as not representing a discretionary trade by the CEO. After these sales, Leonard Frank X directly holds 459,520 Ordinary Shares.
NovoCure Ltd director Gabriel Leung received new equity awards as part of compensation. He was granted 11,610 Ordinary Shares in the form of restricted stock units at no cost, increasing his direct holdings to 101,109 Ordinary Shares.
He also received stock options for 16,999 Ordinary Shares at an exercise price of $16.15 per share, expiring on June 3, 2036. Both the restricted stock units and the options are scheduled to vest 100% on the earlier of the first anniversary of the June 3, 2026 grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders.
NovoCure Ltd director Kristin Stafford received new equity awards. She was granted 11,610 ordinary shares in the form of restricted stock units at no cash cost, increasing her direct holdings to 22,934 ordinary shares.
She also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share. According to the award terms, the restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders. The options are scheduled to vest and become fully exercisable on the same timetable.